BRODSKY & SMITH INVESTOR ALERT: Updates on Investigations Involving TrueCar, Inc. (Nasdaq – TRUE), Astria Therapeutics, Inc. (Nasdaq – ATXS), PotlatchDeltic Corporation (Nasdaq – PCH), and SWK Holdings Corporation (Nasdaq – SWKH)
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 16 2025
0mins
Source: Globenewswire
TrueCar Acquisition Investigation: TrueCar, Inc. is set to be acquired by Fair Holdings for $2.55 per share, prompting an investigation into whether the Board breached fiduciary duties by not ensuring a fair process and value for shareholders.
Astria Therapeutics Merger Scrutiny: Astria Therapeutics, Inc. will be acquired by BioCryst Pharmaceuticals for an implied value of $13.00 per share, leading to an investigation regarding the Board's adherence to fiduciary duties in the merger process.
PotlatchDeltic Corporation Deal Review: PotlatchDeltic Corporation is being acquired by Rayonier, with shareholders receiving shares valued at $44.11 each, raising concerns about the Board's fiduciary responsibilities in ensuring fair value during the transaction.
SWK Holdings Corporation Acquisition Inquiry: SWK Holdings Corporation will merge with Runway Growth Finance Corp. in a deal valued at approximately $220 million, with investigations focusing on the Board's duty to conduct a fair process and provide adequate value to shareholders.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BCRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BCRX
Wall Street analysts forecast BCRX stock price to rise
11 Analyst Rating
9 Buy
2 Hold
0 Sell
Strong Buy
Current: 8.500
Low
8.00
Averages
19.45
High
32.00
Current: 8.500
Low
8.00
Averages
19.45
High
32.00
About BCRX
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of HAE attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX17725, navenibart, Avoralstat, STAR-0310, RAPIACTA (peramivir injection) and PERAMIFLU (peramivir injection). The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older. Peramivir injection is also approved in Canada (RAPIVAB), Australia (RAPIVAB), Japan (RAPIACTA), Taiwan (RAPIACTA), and Korea (PERAMIFLU). It has also obtained an early-stage program for atopic dermatitis (AD), STAR0310.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BioCryst Releases New Data on ORLADEYO and Navenibart
- ORLADEYO Efficacy: In the APeX-P study, patients treated with ORLADEYO experienced only 0.169 hereditary angioedema (HAE) attacks per month, a significant reduction from 0.691 attacks on standard-of-care therapies, highlighting the drug's effectiveness in lowering attack frequency.
- Standard Treatment Comparison: Over a 12-week observation period, patients on standard treatment averaged 22 HAE attacks, which dropped to just 3 attacks with ORLADEYO, indicating its potential to significantly improve patients' quality of life through long-term prevention of HAE attacks.
- Navenibart Development Progress: BioCryst is developing Navenibart as a long-acting treatment, with preliminary data showing effective reduction of moderate to severe HAE attacks across various body mass index (BMI) and age groups, supporting its application in future clinical trials.
- Clinical Trial Support: The Phase 1b/2 ALPHA-STAR trial results for Navenibart indicate reduced on-demand medication use among treated patients, with good drug tolerability, laying the groundwork for its upcoming Phase 3 ALPHA-ORBIT trial, which could offer new treatment options for HAE patients.
See More
BioCryst Reaffirms ORLADEYO Revenue Guidance Amid Navenibart Trial Progress
- Revenue Guidance Reaffirmed: BioCryst reaffirms its 2023 ORLADEYO revenue guidance of $625 million to $645 million, with Q1 revenue at $148.3 million aligning with expectations, indicating strong patient demand and reimbursement trends that are expected to drive U.S. sales towards the $1 billion target.
- Pediatric Launch Delayed: The pediatric launch of ORLADEYO was delayed due to a batch-specific manufacturing issue, which is deemed isolated and non-safety-related; early prescriptions have exceeded expectations, indicating strong market demand, and once available, this could positively impact sales.
- Navenibart Trial Progress: BioCryst's navenibart Phase 3 trial is nearing completion of enrollment, with top-line data expected in Q3 next year and a BLA filing planned by the end of 2027, showcasing the company's ongoing R&D advancements in rare diseases.
- Strong Financial Position: BioCryst reported a cash position of $330 million at the end of Q1, with expectations of profitability this year and increased profitability next year, reflecting robust development in both commercialization and R&D efforts.
See More
BioCryst Pharmaceuticals Q1 2026 Earnings Call Highlights
- Strong Financial Performance: BioCryst reported ORLADEYO net revenue of $148.3 million for Q1 2026, aligning with expectations and reflecting a 21% year-over-year increase, indicating robust market demand and sustained revenue growth potential.
- R&D Progress on Track: The pivotal ALPHA-ORBIT trial for navenibart has exceeded expectations, with approximately 145 patients expected to be enrolled by the end of next month, laying the groundwork for future regulatory submissions and enhancing the company's competitive position in the rare disease space.
- Market Competition Management: Despite facing new competition, demand for new prescriptions among patients aged 12 and older remains stable, demonstrating continued trust in ORLADEYO from both physicians and patients, which is expected to drive further market share growth.
- Supply Chain Challenges: Although a manufacturing issue for pediatric formulations has been identified that will delay initial product fulfillment, management has stated that this delay will not impact the revenue guidance for 2026, reflecting the company's confidence in future performance.
See More
BioCryst Pharmaceuticals Q1 Earnings Analysis
- Disappointing Earnings: BioCryst Pharmaceuticals reported a Q1 GAAP EPS of -$2.98, missing expectations by $3.03, indicating challenges in profitability that could negatively impact investor confidence.
- Revenue Growth: The company achieved Q1 revenue of $156.4 million, a 7.5% year-over-year increase, exceeding expectations by $5.28 million, suggesting sustained demand for its products and potentially laying a foundation for future financial performance.
- 2026 Financial Outlook: BioCryst maintained its expectation for global net ORLADEYO revenue in 2026 to be between $625 million and $645 million, reflecting confidence in its core product while indicating stability in future revenue projections.
- Operating Expense Projections: The company expects non-GAAP operating expenses for 2026 to remain between $450 million and $470 million, indicating ongoing efforts to control costs, which may aid in achieving profitability in the future.
See More
BioCryst Pharmaceuticals to Announce Q1 Earnings on May 6
- Earnings Announcement: BioCryst Pharmaceuticals (BCRX) is set to announce its Q1 2023 earnings on May 6 before the market opens, with consensus EPS estimated at $0.11 and revenue expected to reach $151.12 million, reflecting a 3.9% year-over-year growth.
- Historical Performance: Over the past two years, BCRX has beaten EPS estimates 50% of the time and revenue estimates 88% of the time, indicating a level of stability and confidence in the company's financial performance.
- Estimate Revision Trends: In the last three months, there have been no upward revisions to EPS estimates and one downward revision, while revenue estimates saw one upward revision but four downward revisions, suggesting a cautious outlook from the market regarding the company's future performance.
- Future Revenue Target: BioCryst has set a revenue target of $625 million to $645 million for ORLADEYO in 2026, as the HAE pipeline advances, demonstrating the company's positive outlook for future growth opportunities.
See More
BioCryst Appoints New Chief R&D Officer to Drive Rare Disease Strategy
- New R&D Leadership: BioCryst Pharmaceuticals has appointed Dr. Sandeep M. Menon as Chief Research and Development Officer, bringing a wealth of experience from Alnylam Pharmaceuticals that is expected to invigorate the company's focus on rare disease therapies.
- New Strategic Phase: Following the acquisition of Astria Therapeutics and the navenibart program, BioCryst is entering a new phase of execution aimed at enhancing company value through the development and commercialization of rare disease therapies.
- Clinical Development Achievements: Dr. Menon previously led the FDA approval of AMVUTTRA® at Alnylam, showcasing his exceptional capabilities in managing complex programs and scaling global R&D organizations, which will aid BioCryst in improving its R&D success rates.
- Future Growth Potential: The addition of Dr. Menon is seen as a critical inflection point for BioCryst in the rare disease sector, with expectations that he will drive continued growth in the development of innovative therapies and market expansion.
See More
BioCryst Releases New Data on ORLADEYO and Navenibart
- ORLADEYO Efficacy: In the APeX-P study, patients treated with ORLADEYO experienced only 0.169 hereditary angioedema (HAE) attacks per month, a significant reduction from 0.691 attacks on standard-of-care therapies, highlighting the drug's effectiveness in lowering attack frequency.
- Standard Treatment Comparison: Over a 12-week observation period, patients on standard treatment averaged 22 HAE attacks, which dropped to just 3 attacks with ORLADEYO, indicating its potential to significantly improve patients' quality of life through long-term prevention of HAE attacks.
- Navenibart Development Progress: BioCryst is developing Navenibart as a long-acting treatment, with preliminary data showing effective reduction of moderate to severe HAE attacks across various body mass index (BMI) and age groups, supporting its application in future clinical trials.
- Clinical Trial Support: The Phase 1b/2 ALPHA-STAR trial results for Navenibart indicate reduced on-demand medication use among treated patients, with good drug tolerability, laying the groundwork for its upcoming Phase 3 ALPHA-ORBIT trial, which could offer new treatment options for HAE patients.
See More
BioCryst Reaffirms ORLADEYO Revenue Guidance Amid Navenibart Trial Progress
- Revenue Guidance Reaffirmed: BioCryst reaffirms its 2023 ORLADEYO revenue guidance of $625 million to $645 million, with Q1 revenue at $148.3 million aligning with expectations, indicating strong patient demand and reimbursement trends that are expected to drive U.S. sales towards the $1 billion target.
- Pediatric Launch Delayed: The pediatric launch of ORLADEYO was delayed due to a batch-specific manufacturing issue, which is deemed isolated and non-safety-related; early prescriptions have exceeded expectations, indicating strong market demand, and once available, this could positively impact sales.
- Navenibart Trial Progress: BioCryst's navenibart Phase 3 trial is nearing completion of enrollment, with top-line data expected in Q3 next year and a BLA filing planned by the end of 2027, showcasing the company's ongoing R&D advancements in rare diseases.
- Strong Financial Position: BioCryst reported a cash position of $330 million at the end of Q1, with expectations of profitability this year and increased profitability next year, reflecting robust development in both commercialization and R&D efforts.
See More
BioCryst Pharmaceuticals Q1 2026 Earnings Call Highlights
- Strong Financial Performance: BioCryst reported ORLADEYO net revenue of $148.3 million for Q1 2026, aligning with expectations and reflecting a 21% year-over-year increase, indicating robust market demand and sustained revenue growth potential.
- R&D Progress on Track: The pivotal ALPHA-ORBIT trial for navenibart has exceeded expectations, with approximately 145 patients expected to be enrolled by the end of next month, laying the groundwork for future regulatory submissions and enhancing the company's competitive position in the rare disease space.
- Market Competition Management: Despite facing new competition, demand for new prescriptions among patients aged 12 and older remains stable, demonstrating continued trust in ORLADEYO from both physicians and patients, which is expected to drive further market share growth.
- Supply Chain Challenges: Although a manufacturing issue for pediatric formulations has been identified that will delay initial product fulfillment, management has stated that this delay will not impact the revenue guidance for 2026, reflecting the company's confidence in future performance.
See More
BioCryst Pharmaceuticals Q1 Earnings Analysis
- Disappointing Earnings: BioCryst Pharmaceuticals reported a Q1 GAAP EPS of -$2.98, missing expectations by $3.03, indicating challenges in profitability that could negatively impact investor confidence.
- Revenue Growth: The company achieved Q1 revenue of $156.4 million, a 7.5% year-over-year increase, exceeding expectations by $5.28 million, suggesting sustained demand for its products and potentially laying a foundation for future financial performance.
- 2026 Financial Outlook: BioCryst maintained its expectation for global net ORLADEYO revenue in 2026 to be between $625 million and $645 million, reflecting confidence in its core product while indicating stability in future revenue projections.
- Operating Expense Projections: The company expects non-GAAP operating expenses for 2026 to remain between $450 million and $470 million, indicating ongoing efforts to control costs, which may aid in achieving profitability in the future.
See More
BioCryst Pharmaceuticals to Announce Q1 Earnings on May 6
- Earnings Announcement: BioCryst Pharmaceuticals (BCRX) is set to announce its Q1 2023 earnings on May 6 before the market opens, with consensus EPS estimated at $0.11 and revenue expected to reach $151.12 million, reflecting a 3.9% year-over-year growth.
- Historical Performance: Over the past two years, BCRX has beaten EPS estimates 50% of the time and revenue estimates 88% of the time, indicating a level of stability and confidence in the company's financial performance.
- Estimate Revision Trends: In the last three months, there have been no upward revisions to EPS estimates and one downward revision, while revenue estimates saw one upward revision but four downward revisions, suggesting a cautious outlook from the market regarding the company's future performance.
- Future Revenue Target: BioCryst has set a revenue target of $625 million to $645 million for ORLADEYO in 2026, as the HAE pipeline advances, demonstrating the company's positive outlook for future growth opportunities.
See More
BioCryst Appoints New Chief R&D Officer to Drive Rare Disease Strategy
- New R&D Leadership: BioCryst Pharmaceuticals has appointed Dr. Sandeep M. Menon as Chief Research and Development Officer, bringing a wealth of experience from Alnylam Pharmaceuticals that is expected to invigorate the company's focus on rare disease therapies.
- New Strategic Phase: Following the acquisition of Astria Therapeutics and the navenibart program, BioCryst is entering a new phase of execution aimed at enhancing company value through the development and commercialization of rare disease therapies.
- Clinical Development Achievements: Dr. Menon previously led the FDA approval of AMVUTTRA® at Alnylam, showcasing his exceptional capabilities in managing complex programs and scaling global R&D organizations, which will aid BioCryst in improving its R&D success rates.
- Future Growth Potential: The addition of Dr. Menon is seen as a critical inflection point for BioCryst in the rare disease sector, with expectations that he will drive continued growth in the development of innovative therapies and market expansion.
See More
